Imatinib Cipla (Imatinib)

Imatinib blocks the activity of the BCR‑ABL fusion protein as well as KIT and PDGFRA kinases by occupying their ATP‑binding sites. This inhibition stops downstream signaling pathways that drive uncontrolled cell division, leading to reduced proliferation of malignant cells and, in many cases, tumor regression.

The dosage of Imatinib Cipla is individualized by the prescribing clinician based on the specific indication, disease stage, patient weight, renal and hepatic function, and response to therapy. Only a qualified health‑care professional should determine the appropriate dose and schedule.

Safety data for Imatinib in pregnancy and lactation are limited. The drug may cross the placenta and be excreted in breast milk, potentially causing fetal or neonatal harm. Use only if the potential benefit justifies the risk, and discuss alternatives with a specialist.

To place an order, submit an enquiry on the Imatinib Cipla product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative to Imatinib in chronic myeloid leukemia is dasatinib, a second‑generation tyrosine‑kinase inhibitor. Dasatinib has a broader kinase inhibition profile and may be effective in some Imatinib‑resistant cases, but it also carries a different safety spectrum, including higher rates of pleural effusion. Choice depends on disease characteristics, prior therapy, and patient tolerance.

Imatinib Cipla tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect the product from excess moisture, heat, and direct sunlight. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Imatinib Cipla is taken orally, usually once daily, with a glass of water. It can be swallowed with or without food; however, a consistent approach (with or without meals) is recommended to maintain stable absorption. Swallow the tablet whole; do not crush or chew unless instructed by a health‑care professional.

The most serious adverse events include severe neutropenia or other cytopenias, hepatotoxicity manifested by marked liver enzyme elevations, and cardiac failure, especially in patients with pre‑existing heart disease. Prompt reporting of fever, jaundice, shortness of breath, or unexplained swelling to a clinician is essential.

Imatinib is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Patients with severe hepatic impairment, uncontrolled cardiac disease, or those receiving prohibited concomitant medications (e.g., strong CYP3A4 inhibitors) should avoid the drug unless a specialist determines that benefits outweigh risks.